According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Senna, Gianenrico;Calabrese, Cecilia;Caminati, Marco;Corsico, Angelo G;Guida, Giuseppe;
2020-01-01

Abstract

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.
2020
Biologics
CRSwNP, chronic rhinosinusitis with nasal polyposis
EMA, European Medicines Agency
FDA, Food & Drug Administration
FEV1, forced expiratory volume in the 1st second
GINA, Global Initiative for Asthma
GRADE, Grading of Recommendations Assessment, Development and Evaluation
ISAR, International Severe Asthma Registry
OCSs, Oral CorticoSteroids
Oral corticosteroids
RW, Real World
Real-life
Registr
SA, severe asthma
SANI, Severe Asthma Network in Italy
SARP, Severe Asthma Research Program
SHARP, Severe Heterogeneous Asthma Research collaboration, Patient-centred
Severe asthma
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1025740
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 31
social impact